{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T11:45:09Z","timestamp":1753875909790,"version":"3.41.2"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T00:00:00Z","timestamp":1639612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003510","name":"Ministry of Education and Research","doi-asserted-by":"publisher","award":["01GM1908A"],"award-info":[{"award-number":["01GM1908A"]}],"id":[{"id":"10.13039\/501100003510","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Although most of the progressive multifocal leukoencephalopathy cases in sarcoidosis patients are explained by the treatment with immunosuppressive drugs, it is also reported in treatment-naive sarcoidosis patients, which implies a general predisposition of sarcoidosis patients for progressive multifocal leukoencephalopathy. Indeed, it was shown that active sarcoidosis patients have increased regulatory T cell frequencies which could lead to a subsequent systemic immunosuppression. However, if sarcoidosis with systemic changes of T cell subsets frequencies constitute a risk factor for the development of progressive multifocal leukoencephalopathy, which could then be counteracted by sarcoidosis treatment, is not known. In this cohort study, we included, characterized and followed-up six patients with bioptically confirmed definite progressive multifocal leukoencephalopathy and definite or probable sarcoidosis presenting between April 2013 and January 2019, four of them had no immunosuppressive therapy at the time of developing first progressive multifocal leukoencephalopathy symptoms. Analysis of immune cell subsets in these patients revealed significant imbalances of CD4+ T cell and regulatory T cell frequencies. Due to the progression of progressive multifocal leukoencephalopathy in four patients, we decided to treat sarcoidosis anticipating normalization of immune cell subset frequencies and thereby improving progressive multifocal leukoencephalopathy. Notably, by treatment with infliximab, an antibody directed against tumour necrosis factor-\u03b1, three patients continuously improved clinically, JC virus was no longer detectable in the cerebrospinal fluid and regulatory T cell frequencies decreased. One patient was initially misdiagnosed as neurosarcoidosis and died 9 weeks after treatment initiation due to aspiration pneumonia. Our study provides insight that sarcoidosis can lead to changes in T cell subset frequencies, which predisposes to progressive multifocal leukoencephalopathy. Although immunosuppressive drugs should be avoided in progressive multifocal leukoencephalopathy, paradoxically in patients with sarcoidosis treatment with the immunosuppressive infliximab might restore normal T cell distribution and thereby halt progressive multifocal leukoencephalopathy progression.<\/jats:p>","DOI":"10.1093\/braincomms\/fcab292","type":"journal-article","created":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T20:08:55Z","timestamp":1639253335000},"source":"Crossref","is-referenced-by-count":1,"title":["Treating sarcoidosis-associated progressive multifocal leukoencephalopathy with infliximab"],"prefix":"10.1093","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5228-4266","authenticated-orcid":false,"given":"Sina C.","family":"Rosenkranz","sequence":"first","affiliation":[{"name":"Institute of Neuroimmunology and Multiple Sclerosis, University Medical Center Hamburg-Eppendorf, Germany"},{"name":"Department of Neurology, University Medical Center Hamburg-Eppendorf, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivien","family":"H\u00e4u\u00dfler","sequence":"additional","affiliation":[{"name":"Institute of Neuroimmunology and Multiple Sclerosis, University Medical Center Hamburg-Eppendorf, Germany"},{"name":"Department of Neurology, University Medical Center Hamburg-Eppendorf, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Kolster","sequence":"additional","affiliation":[{"name":"Department of Immunology, University Medical Center Hamburg-Eppendorf, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Willing","sequence":"additional","affiliation":[{"name":"Institute of Neuroimmunology and Multiple Sclerosis, University Medical Center Hamburg-Eppendorf, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakob","family":"Matschke","sequence":"additional","affiliation":[{"name":"Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"R\u00f6cken","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University Medical Center Schleswig-Holstein, Kiel, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klarissa","family":"St\u00fcrner","sequence":"additional","affiliation":[{"name":"Neuroimmunology, Institute of Clinical Chemistry, University Medical Center Schleswig-Holstein, Kiel, Germany"},{"name":"Department of Neurology, University Medical Center Schleswig-Holstein and Kiel University, Kiel, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Leypoldt","sequence":"additional","affiliation":[{"name":"Neuroimmunology, Institute of Clinical Chemistry, University Medical Center Schleswig-Holstein, Kiel, Germany"},{"name":"Department of Neurology, University Medical Center Schleswig-Holstein and Kiel University, Kiel, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Tolosa","sequence":"additional","affiliation":[{"name":"Department of Immunology, University Medical Center Hamburg-Eppendorf, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6380-2420","authenticated-orcid":false,"given":"Manuel A.","family":"Friese","sequence":"additional","affiliation":[{"name":"Institute of Neuroimmunology and Multiple Sclerosis, University Medical Center Hamburg-Eppendorf, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,12,16]]},"reference":[{"issue":"12","key":"2022021509242974600_fcab292-B1","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/nrneurol.2010.164","article-title":"Progressive multifocal leukoencephalopathy and other forms of JC virus disease","volume":"6","author":"Brew","year":"2010","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"2022021509242974600_fcab292-B2","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1136\/jnnp.2009.187666","article-title":"Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression","volume":"81","author":"Gheuens","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"2022021509242974600_fcab292-B3","doi-asserted-by":"crossref","first-page":"566\u2013e41","DOI":"10.1111\/ene.13906","article-title":"The spectrum of progressive multifocal leukoencephalopathy: a practical approach","volume":"26","author":"Bartsch","year":"2019","journal-title":"Eur J Neurol"},{"issue":"9923","key":"2022021509242974600_fcab292-B4","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(13)60680-7","article-title":"Sarcoidosis","volume":"383","author":"Valeyre","year":"2014","journal-title":"Lancet"},{"issue":"15","key":"2022021509242974600_fcab292-B5","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1212\/WNL.0000000000000318","article-title":"Progressive multifocal leukoencephalopathy in patients with sarcoidosis","volume":"82","author":"Jamilloux","year":"2014","journal-title":"Neurology"},{"issue":"7","key":"2022021509242974600_fcab292-B6","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.clineuro.2007.05.009","article-title":"Progressive multifocal leukoencephalopathy developing in advanced pulmonal sarcoidosis","volume":"109","author":"V\u00f6lker","year":"2007","journal-title":"Clin Neurol Neurosurg"},{"issue":"11","key":"2022021509242974600_fcab292-B7","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1002\/ccr3.1816","article-title":"Can pulmonary sarcoidosis trigger a progressive multifocal leukoencephalopathy? Considerations from a case series and a review of literature","volume":"6","author":"Gamperl","year":"2018","journal-title":"Clin Case Rep"},{"key":"2022021509242974600_fcab292-B8","first-page":"bcr0320114036","article-title":"Progressive multi-focal leukoencephalopathy as a rare lethal complication in untreated sarcoidosis","volume":"28","author":"Hohlfeld","year":"2012","journal-title":"BMJ Case Rep"},{"issue":"1","key":"2022021509242974600_fcab292-B9","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/NRL.0b013e31827c6c3d","article-title":"Progressive multifocal leukoencephalopathy as the first manifestation of occult sarcoidosis: case report and review of the literature","volume":"19","author":"Davis","year":"2013","journal-title":"Neurologist"},{"key":"2022021509242974600_fcab292-B10","first-page":"10","article-title":"Posterior fossa progressive multifocal leukoencephalopathy: first presentation of an unknown autoimmune disease","volume":"2017","author":"Scholten","year":"2017","journal-title":"BMJ Case Rep"},{"issue":"2","key":"2022021509242974600_fcab292-B11","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.clineuro.2007.09.012","article-title":"Progressive multifocal leukoencephalopathy as first manifestation of sarcoidosis","volume":"110","author":"De Raedt","year":"2008","journal-title":"Clin Neurol Neurosurg"},{"issue":"2","key":"2022021509242974600_fcab292-B12","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1084\/jem.20050648","article-title":"The immune paradox of sarcoidosis and regulatory T cells","volume":"203","author":"Miyara","year":"2006","journal-title":"J Exp Med"},{"issue":"15","key":"2022021509242974600_fcab292-B13","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1212\/WNL.0b013e31828c2fa1","article-title":"PML diagnostic criteria: Consensus statement from the AAN neuroinfectious disease section","volume":"80","author":"Berger","year":"2013","journal-title":"Neurology"},{"issue":"10","key":"2022021509242974600_fcab292-B14","doi-asserted-by":"crossref","first-page":"4986","DOI":"10.4049\/jimmunol.170.10.4986","article-title":"Differential control of cell cycle, proliferation, and survival of primary T lymphocytes by purine and pyrimidine nucleotides","volume":"170","author":"Qu\u00e9m\u00e9neur","year":"2003","journal-title":"J Immunol"},{"issue":"11","key":"2022021509242974600_fcab292-B15","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1093\/cid\/ciu682","article-title":"Treating progressive multifocal leukoencephalopathy with interleukin 7 and vaccination with JC virus capsid protein VP1","volume":"59","author":"Sospedra","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2022021509242974600_fcab292-B16","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.autrev.2014.10.006","article-title":"The spectrum of opportunistic diseases complicating sarcoidosis","volume":"14","author":"Jamilloux","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"1","key":"2022021509242974600_fcab292-B17","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1186\/s12879-020-05174-5","article-title":"Sarcoidosis with cryptococcal infection apparently engaging only immune-privileged body compartments: a case report","volume":"20","author":"van der Stoep","year":"2020","journal-title":"BMC Infect Dis"},{"issue":"49","key":"2022021509242974600_fcab292-B18","doi-asserted-by":"crossref","first-page":"e8846","DOI":"10.1097\/MD.0000000000008846","article-title":"Severe infections in sarcoidosis: Incidence, predictors and long-term outcome in a cohort of 585 patients","volume":"96","author":"Dur\u00e9ault","year":"2017","journal-title":"Medicine"},{"issue":"21","key":"2022021509242974600_fcab292-B19","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1056\/NEJMra071714","article-title":"Sarcoidosis","volume":"357","author":"Iannuzzi","year":"2007","journal-title":"N Engl J Med"},{"key":"2022021509242974600_fcab292-B20","doi-asserted-by":"crossref","first-page":"e313","DOI":"10.1016\/j.ijid.2010.02.2257","article-title":"Spontaneous recovery from progressive multifocal leukoencephalopathy in a patient with non-active sarcoidosis","volume":"14","author":"Goldbecker","year":"2010","journal-title":"Int J Infect Dis"},{"issue":"6","key":"2022021509242974600_fcab292-B21","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1177\/1352458516667241","article-title":"Predictors of severity and functional outcome in natalizumab-associated progressive multifocal leukoencephalopathy","volume":"23","author":"Hoepner","year":"2017","journal-title":"Mult Scler J"},{"issue":"6","key":"2022021509242974600_fcab292-B22","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1086\/314496","article-title":"Prognostic value of JC virus load in cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy","volume":"178","author":"Taoufik","year":"1998","journal-title":"J Infect Dis"},{"issue":"17","key":"2022021509242974600_fcab292-B23","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa1815039","article-title":"Pembrolizumab treatment for progressive multifocal leukoencephalopathy","volume":"380","author":"Cortese","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"2022021509242974600_fcab292-B24","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/0092-8674(89)90676-4","article-title":"The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection","volume":"56","author":"Kindler","year":"1989","journal-title":"Cell"},{"issue":"8","key":"2022021509242974600_fcab292-B25","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJM198108203050804","article-title":"Pulmonary sarcoidosis","volume":"305","author":"Hunninghake","year":"1981","journal-title":"N Engl J Med"},{"key":"2022021509242974600_fcab292-B26","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.cyto.2016.08.003","article-title":"TNF activity and T cells amit","volume":"101","author":"Mehta","year":"2018","journal-title":"Cytokine"},{"issue":"2","key":"2022021509242974600_fcab292-B27","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/cei.12808","article-title":"Infliximab therapy balances regulatory T cells, tumour necrosis factor receptor 2 (TNFR2) expression and soluble TNFR2 in sarcoidosis","volume":"185","author":"Verwoerd","year":"2016","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"2022021509242974600_fcab292-B28","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nri2526","article-title":"The role of TNF superfamily members in T-cell function and diseases","volume":"9","author":"Croft","year":"2009","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"2022021509242974600_fcab292-B29","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1378\/chest.09-2576","article-title":"The CD4+ lymphopenic sarcoidosis phenotype is highly responsive to anti-tumor necrosis factor-\u03b1 therapy","volume":"137","author":"Crouser","year":"2010","journal-title":"Chest"},{"key":"2022021509242974600_fcab292-B30","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3389\/fimmu.2018.00172","article-title":"Establishment of the reference intervals of lymphocyte function in healthy adults based on IFN-\u03b3 secretion assay upon phorbol-12-myristate-13-acetate\/ionomycin stimulation","volume":"9","author":"Hou","year":"2018","journal-title":"Front Immunol"},{"issue":"11","key":"2022021509242974600_fcab292-B31","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1002\/art.27687","article-title":"A case of progressive multifocal leukoencephalopathy in a patient treated with infliximab","volume":"62","author":"Kumar","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"9","key":"2022021509242974600_fcab292-B32","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1002\/art.34468","article-title":"Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: Evolving role of biologic therapies","volume":"64","author":"Molloy","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"5","key":"2022021509242974600_fcab292-B33","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/ana.1004","article-title":"Cellular and humoral immune response in progressive multifocal leukoencephalopathy","volume":"49","author":"Weber","year":"2001","journal-title":"Ann Neurol"},{"issue":"1\u20132","key":"2022021509242974600_fcab292-B34","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jneuroim.2010.11.013","article-title":"Role for tumor necrosis factor-alpha in JC virus reactivation and progressive multifocal leukoencephalopathy","volume":"233","author":"Wollebo","year":"2011","journal-title":"J Neuroimmunol"},{"issue":"5","key":"2022021509242974600_fcab292-B35","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1378\/chest.98.5.1125","article-title":"Serum concentration of soluble interleukin-2 receptor as a sensitive parameter of disease activity in sarcoidosis","volume":"98","author":"Keicho","year":"1990","journal-title":"Chest"},{"issue":"10","key":"2022021509242974600_fcab292-B36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0223897","article-title":"Sensitivity and specificity of serum soluble interleukin-2 receptor for diagnosing sarcoidosis in a population of patients suspected of sarcoidosis","volume":"14","author":"Eurelings","year":"2019","journal-title":"PLoS One"},{"issue":"5","key":"2022021509242974600_fcab292-B37","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1164\/ajrccm.156.5.97-02050","article-title":"Sarcoidosis: TNF-\u03b1 release from alveolar macrophages and serum level of sIL-2R are prognostic markers","volume":"156","author":"Ziegenhagen","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"2022021509242974600_fcab292-B38","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00408-015-9826-3","article-title":"Diagnostic utility of angiotensin converting enzyme in sarcoidosis: a population-based study","volume":"194","author":"Ungprasert","year":"2016","journal-title":"Lung"},{"issue":"11","key":"2022021509242974600_fcab292-B39","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1080\/1744666X.2016.1196135","article-title":"Biomarkers in sarcoidosis","volume":"12","author":"Chopra","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"issue":"3","key":"2022021509242974600_fcab292-B40","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/nri3156","article-title":"The role of interleukin-2 during homeostasis and activation of the immune system","volume":"12","author":"Boyman","year":"2012","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"2022021509242974600_fcab292-B41","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/ni.3540","article-title":"An essential role for IL-2 receptor in regulatory T cell function","volume":"17","author":"Chinen","year":"2016","journal-title":"Nat Immunol"},{"issue":"3","key":"2022021509242974600_fcab292-B42","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s12016-012-8327-x","article-title":"Systemic lupus erythematosus, progressive multifocal leukoencephalopathy, and T-CD4+ lymphopenia","volume":"43","author":"Brand\u00e3o","year":"2012","journal-title":"Clin Rev Allergy Immunol"},{"issue":"2","key":"2022021509242974600_fcab292-B43","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.autrev.2008.07.006","article-title":"Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk?","volume":"8","author":"Molloy","year":"2008","journal-title":"Autoimmun Rev"}],"container-title":["Brain Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/braincomms\/advance-article-pdf\/doi\/10.1093\/braincomms\/fcab292\/41787236\/fcab292.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/4\/1\/fcab292\/42471673\/fcab292.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/4\/1\/fcab292\/42471673\/fcab292.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T09:27:11Z","timestamp":1644917231000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/braincomms\/article\/doi\/10.1093\/braincomms\/fcab292\/6464118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,16]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,4]]}},"URL":"https:\/\/doi.org\/10.1093\/braincomms\/fcab292","relation":{},"ISSN":["2632-1297"],"issn-type":[{"type":"electronic","value":"2632-1297"}],"subject":[],"published-other":{"date-parts":[[2022,2,1]]},"published":{"date-parts":[[2021,12,16]]},"article-number":"fcab292"}}